NCT03944772: An ongoing trial by AstraZeneca
This trial is ongoing. It must report results 7 months, 3 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT03944772 |
|---|---|
| Title | A Biomarker-directed Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy. |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 25, 2019 |
| Completion date | May 6, 2025 |
| Required reporting date | May 6, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Sept. 11, 2025 |
| Days late | None |